Arcus Biosciences Q2 2024 GAAP EPS $(1.02) Beats $(1.18) Estimate, Sales $39.000M Beat $25.613M Estimate
Author: Benzinga Newsdesk | August 08, 2024 04:10pm
Arcus Biosciences (NYSE:
RCUS) reported quarterly losses of $(1.02) per share which beat the analyst consensus estimate of $(1.18) by 13.56 percent. The company reported quarterly sales of $39.000 million which beat the analyst consensus estimate of $25.613 million by 52.27 percent. This is a 34.48 percent increase over sales of $29.000 million the same period last year.
Posted In: RCUS